Comparing two supplements (Cynacol vs Metacol) for lowering LDL cholesterol in mild high cholesterol
Official title: Randomized and Comparative Clinical Study on the Lipid-lowering Efficacy and Tolerability of Two Food Supplements in Mild Hypercholesterolemia
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07295327 · Data updated 2026-11-12
This test will see if the supplement Cynacol lowers LDL cholesterol more than Metacol in adults aged 35–70 with mild high LDL (115–190 mg/dL).
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 35 Years to 70 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia, Lombardy) |
| Status | Recruiting |
| Started | September 30, 2025 |
| Main results expected | March 31, 2026 |
| Study ends | March 31, 2026 |
| Registry record updated | December 19, 2025 |
| Trial ID | NCT07295327 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 35–70 with LDL cholesterol between 115 and 190 mg/dL who are not on lipid-lowering medications, without diabetes, obesity (BMI ≥30), cardiovascular disease, or major liver/kidney/muscle disorders.
✕Probably not a fit
People with very high LDL, diabetes, obesity (BMI ≥30), established cardiovascular disease, or those already taking statins or other lipid-lowering therapies are unlikely to benefit from these supplements in this study context.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, two-arm, 90-day intervention comparing the effects of Cynacol and Metacol on lipid levels in adults with mild hypercholesterolemia. Participants will have blood tests and vital signs measured at baseline, 45 days, and 90 days, and will receive standardized diet and activity advice. The primary outcome is change in LDL-C after 90 days, with secondary outcomes including total cholesterol, non-HDL-C, apoB, triglycerides, and HDL-C; safety is monitored by recording adverse events and routine labs. Eligible adults (35–70 years) are those with LDL 115–190 mg/dL who are not taking lipid-lowering drugs and without diabetes, significant obesity, or major organ disease.
Why it matters
Potential benefit: If successful, the supplement could offer a modest, non-prescription option to lower LDL cholesterol for people with mild hypercholesterolemia.
How similar studies have gone: Some prior trials of dietary supplements have shown modest lipid improvements, but direct head-to-head data specifically comparing Cynacol and Metacol are limited or novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age between 35-70 years * both genders * LDL-C levels between 115 and 190 mg/dl * subjects able to understand the informed consent and sign it before enrollment in the study Exclusion Criteria: * personal history of cardiovascular disease or equivalent risk factors * Tg levels ≥ 400 mg/dl * obesity \[body mass index (BMI) ≥ 30 kg/m²\] * taking hypolipidemic drugs or supplements that affect lipid metabolism * diabetes mellitus * known thyroid, liver, kidney or muscle diseases * any medical or surgical condition that makes patient compliance with the study protocol complex or inconsistent * any known allergy or hypersensitivity to one or more components of the food supplements
Where it's running
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VERVE-102 for adults with or at high risk for heart disease
This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.
-
Enlicitide (MK-0616) for adults with high cholesterol in India
This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.
-
Pemafibrate in people with high cholesterol not fully controlled by statins
This study tests whether taking Pemafibrate at 0.2 mg or 0.4 mg daily for 12 weeks helps people with high cholesterol who still don’t respond well to statins, compared with a placebo.
-
Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance
This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.
-
Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD
In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.
-
Corn oil versus avocado oil effects on cardiometabolic risk factors
This trial will test whether following controlled diets containing either corn oil or avocado oil for 21 days changes cardiometabolic risk factors in adults with mildly to moderately high non‑HDL cholesterol.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.